Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 9
Submit an article Journal homepage
160
Views
45
CrossRef citations to date
0
Altmetric
Miscellaneous

Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts

Pierre Reusser Division of Medicine, Hôpital régional, CH-2900 Porrentruy, Switzerland, Tel.: +41 32 465 65 76; Fax: +41 32 465 69 78;, E-mail: [email protected]
Pages 1745-1753 | Published online: 24 Feb 2005

Bibliography

  • MEIER JL, STRAUS SE: Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. Infect. Dis (1992) 166\(Suppl. 1):513–523.
  • STRAUS SE, COHEN JI, TOSATO G, METER J: Epstein-Barr virus infections: biology, pathogenesis, and management. Ann. Intern. Med. (1993) 118:45–58.
  • SINGH N, CARRIGAN DR: Human herpesvirus-6 in transplantation: an emerging pathogen. Ann. Intern. Med. (1996) 124:1065–1071.
  • REUSSER P, ATTENHOFER R, HEBART H, HELG C, CHAPUIS B, EINSELE H: Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood (1997) 89:3873–3879.
  • REUSSER P, CATHOMAS G, ATTENHOFER R, TAMM M, THIEL G: Cytomegalovirus-specific T-cell immunity after renal transplantation mediates protection from cytomegalovirus disease by limiting the systemic viral load. J. Infect. Dis. (1999) 180:247–253.
  • COHEN JI, BRUNELL PA, STRAUS SE, KRAUSE PR: Recent advances in varicella-zoster virus infection. Ann. Intern. Med. (1999) 130:922–932.
  • DREW WL: Cytomegalovirus infection in patients with AIDS. Clin. Infect. Dis. (1992) 14:608–615.
  • REUSSER P: Cytomegalovirus infection and disease after bone marrow and solid organ transplantation. Bailliere's Clin. Infect. Dis. (1996) 3:357–371.
  • WHITLEY RJ, JACOBSON MA, FRIEDBERG DN et al FOR THE INTERNATIONAL AIDS SOCIETY-USA: Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy. Recommendations of an international panel. Arch. Intern. Med. (1998) 158:957–969.
  • •Recommendations by a broad panel of experts concerning the treatment of CMV disease in patients with AIDS.
  • REUSSER P: Management of viral infections. In: Supportive Care M Cancer: A Handbook for Oncologists (2nd ed). Klastersky J, Schimpff SC, Senn H-J (Eds.), Marcel Dekker, Inc., New York, USA (1999):87–112.
  • JUNG D, DORR A: Single-dose pharmacokinetics of valganciclovir in HIV-and CMV-seropositive subjects. I Clin. Pharmacol (1999) 39:800–804.
  • MEYERS JD, FLOURNOY N, THOMAS ED: Risk factors for cytomegalovirus infection after human marrow transplantation. Infect. Dis. (1986) 153:478–488.
  • ENRIGHT H, HAAKE R, WEISDORF D et al.: Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation (1993) 55:1339–1346.
  • ATKINSON K, NIVISON-SMITH I, DODDS A, CONCANNON A, MILLIKEN S, DOWNS K: A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant. (1998) 21:691–695.
  • LJUNGMAN P, LAMBERTENGHI DELILIERS G, PLATZBECKER U et al: Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood(2001) 97:388–392.
  • GOODRICH JM, BOWDEN RA, FISHER L, KELLER C, SCHOCH G, MEYERS JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. (1993) 118:173–178.
  • WINSTON DJ, HO WG, BARTONI K et Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Merl (1993) 118:179–184.
  • GOODRICH JM, MORI M, GLEAVES CA et al.: Prevention of cytomegalovirus disease after allogeneic marrow transplantation by early treatment with ganciclovir. N Engl.). Med. (1991) 325:1601–1607.
  • •Randomised controlled trial documenting the efficacy of culture-based pre-emptive drug therapy of CMV infection after SCT
  • SCHMIDT GM, HORAK DA, NILAND JC, DUNCAN SR, FORMAN SJ, ZAIA JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl.). Med. (1991) 324:1005–1011.
  • EINSELE H, EHNINGER G, HEBART H et al: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood (1995) 86:2815–2820.
  • •Randomised comparison of pre-emptive therapy of CMV infection based on detection of CMV by PCR in peripheral blood versus viral culture.
  • LJUNGMAN P, ASCHAN J, LEWENSOHN-FUCHS I et al.: Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation (1998) 66:1330–1334.
  • REUSSER P, EINSELE H, LEE Jet al FOR THE INFECTIOUS DISEASES WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION: Randomized, multicenter, open-label trial of foscarnet (FOS) versus ganciclovir (GCV) for preemptive therapy of cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) [abstract]. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1999):432.
  • HIBBERD PL, TOLKOFF-RUBIN NE, COSIMI AB et al.: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation (1992) 53:68–72.
  • CONTI DJ, FREED BM, SINGH TP et al.: Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch. of Surg. (1995) 130:1217–1222.
  • PORTELA D, PATEL R, LARSON-KELLER JJ et al.: OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. Infect. Dis. (1995) 171:1014–1018.
  • PAYA CV: Prevention of cytomegalovirusdisease in recipients of solid-organ transplants. Clin. Infect. Dis (2001) 32:596–603.
  • •Actual review of randomised controlled trials of prevention or pre-emptive therapy of CMV infection after solid organ transplantation.
  • PILLAY D, CHARMAN H, BURROUGHS AK et al.: Surveillance for CMV infection in orthotopic liver transplant recipients. Transplantation (1992) 53:1261–1265.
  • PILLAY D, ALI AA, LIU SF et al: The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation (1993) 56:103–108.
  • ETTINGER NA, BAILEY TC, TRULOCK EP et al: Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am. Rev Resp. Dis. (1993) 147:1017–1023.
  • FOX JC, KIDD IM, GRIFFITHS PD, SWENY P, EMERY VC: Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. Gen. Virol. (1995) 76:309–319.
  • KANJ SS, SHARARA Al, CLAVIEN PA, HAMILTON JD: Cytomegalovirus infection following liver transplantation: review of the literature. Clin. Infect. Dis. (1996) 22:537–549.
  • GANE E, SALIBA E,VALDECASAS JC et al.: Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: results of a multicenter, multinational clinical trial. Lancet (1997) 350:1729–1733.
  • LOWANCE D, NEUMAYER H-H, LEGENDRE et al. FOR THE INTERNATIONAL VALACYCLOVIR CYTOMEGALOVIRUS PROPHYLAXIS TRANSPLANTATION STUDY GROUP: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl. I Med. (1999) 340:1462–1470.
  • POIRIER-TOULEMONDE AS, MILPIED N, CANTAROVICH D, MORCET JF, BILLAUDEL S, IMBERT-MARCILLE BM: Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients. J. Clin. Microbiol. (2000) 38:3143–3149.
  • CAMARGO LF, UIP DE, SIMPSON AA et al.: Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation. Transplantation (2001) 71:412–417.
  • LUMBRERAS C, FERNANDEZ I, VELOSA Jet al.: Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin. Infect. Dis. (1995) 20:514–520.
  • DUNN DL, MAYORAL JL, GILLINGHAM KJ et al: Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation (1991) 51:98–106.
  • MCCARTHY JM, KARIM MA, KRUEGER H, KEOWN PA: The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation (1993) 555:1277–1282.
  • FALAGAS ME, ARBO M, RUTHAZER R et al.: Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation (1997) 63:1595–1601.
  • KIM WR, BADLEY AD, WIESNER RH etal.: The economic impact of cytomegalovirus infection after liver transplantation. Transplantation (2000) 69:357–361.
  • LEGENDRE CM, NORMAN DJ, KEATING MR, MACLAINE GD, GRANT DM: Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation (2000) 70:1463–1468.
  • HART GD, PAYA CV: Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med. Virol. (2001) 11:73–81.
  • BALFOUR HH JR, CHACE BA, STAPLETON JT et al.: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl.' Med (1989) 320:1381–1387.
  • MERIGAN TC, RENLUND DG, KEAY S et al.: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl. I Med. (1992) 326:1182–1186.
  • DUNCAN SR, GRGURICH WF, IACONO AT et al.: A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am. I Resp. Grit. Care Med. (1994) 150:146–152.
  • DUNN DL, GILLINGHAM KJ, KRAMER MA et al.: A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation (1994) 57:876–884.
  • MARTIN M, MAICIEZ R, LINDEN P et al.: A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation (1994) 58:779–785.
  • WINSTON DJ, WIRIN D, SHAKED A et al.: Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet (1995) 346:69–74.
  • FLECHNER SM, AVERY RK, FISHER R et al.: A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation (1998) 66:1682–1688.
  • SINGH N, YU VL, MIELES L et al: High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann. Intern. Med. (1994) 120:375–381.
  • EMERY VC: Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Virol. (2001) 11:83–86.
  • GALLANT JE, MOORE RD, RICHMAN DD et al.: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. I Infect. Dis. (1992) 166:1223–1227.
  • HOOVER DR, SAAH AJ, BACELLAR H et al.: Clinical manifestations of AIDS in the era of pneumocystis carinii prophylaxis. N. Engl. Med. (1993) 329:1922–1926.
  • HOFFMAN VF, SKIEST DJ: Therapeutic developments in cytomegalovirus retinitis. Expert Opin. Investig. Drugs (2000) 9:207–220.
  • LALEZARI JP, STAGG RJ, KUPPERMANN BD et al.: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. (1997) 126:257–263.
  • STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP: Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. A randomized, controlled trial. Ann. Intern. Med. (1997) 126:264–274.
  • THE STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP: Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. AIDS (2000) 14:1571–1581.
  • LALEZARI JP, HOLLAND GN, KRAMER F et al.: Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. I Acquic Immune. Dent.. Syndr: Hum. Retrovirol (1998) 17:339–344.
  • STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP: Combination foscarnet and ganciclovir therapy vsmonotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch. Ophtalmol (1996) 114:23–33.
  • MARTIN DF, KUPPERMANN BD, WOLITZ RA, PALESTINE AG, LI H, ROBINSON CA, AND THE ROCHE GANCICLOVIR STUDY GROUP: Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl.' Med (1999) 340:1063–1070.
  • SPECTOR SA, MCKINLEY GE LALEZARI JP et al AND THE ROCHE COOPERATIVE ORAL GANCICLOVIR STUDY GROUP: Oral ganciclovir for the prevention of cytomegalovirus disease in SO persons with AIDS. N Engl. I Med. (1996) 334:1491–1497.
  • BROSGART CL, LOUIS TA, HILLMAN DW et al.: A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS(1998) 12:269–277.
  • FEINBERG JE, HURWITZ S, COOPER D et al. FOR THE AIDS CLINICAL TRIALS GROUP PROTOCOL 204/ GLAXO WELLCOME 123-014 INTERNATIONAL CMV PROPHYLAXIS STUDY GROUP: A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. Infect. Dis. (1998) 177:48–56.
  • PALTIEL AD, GOLDIE SJ, LOSINA E et al.: Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin. Infect. Dis. (2001) 32:783–793.
  • SUGAWARA M, HUANG W, FEI Y-J, LEIBACH FH, GANAPATHY V, GANAPATHY ME: Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. Phannaceut. Sci. (2000) 89:781–789.
  • BROWN F, BANKEN L, SAY WELL K, ARUM I: Pharmacolkinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin. Phannacokinet. (1999) 37:167-176. esDetailed study of the pharmacokineticsfollowing oral intake of valganciclovir in HIV-infected CMV-seropositive subjects.
  • MARTIN D, SIERRA-MADERO J, WALMSLEY S, WOLITZ R, BROWN F, ROBINSON C, FOR THE ROCHE VALGANCICLOVIR STUDY GROUP: Valganciclovir (VGCV) vs iv ganciclovir (GCV) as induction therapy for newly diagnosed cytomegalovirus (CMV) retinitis. A randomized controlled study. Proceedings of the 7th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2000) (Abstract 231).
  • PESCOVITZ MD, RABKIN J, MERTON RIVI et al.: Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chernother: (2000) 44:2811-2815. Comparative study of the pharmacokinetics following administration of valganciclovir, oral or iv. ganciclovir in liver transplant recipients.

Websites

  • http://www.actis.org ADULT AIDS CLINICAL TRIALS GROUP: A Phase III, prospective, randomized, double-blind trial of valganciclovir pre-emptive therapy for cytomegalovirus (CMV) viremia as detected by plasma CMV DNA PCR assay. Protocol ACTG 5030. [Accessed August 6, 20011.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.